Triastek, a Chinese company that uses additive manufacturing (AM) to develop pharmaceutical therapies, recently completed their first in human (FIH) trial of T21, a medication for ulcerative colitis (UC). This milestone was made possible by Triastek’s Melt Extrusion Deposition (MED) platform, which allowed them to createT21 with unprecedented precision and accuracy. This news is extremely encouraging for the more than 3 million people in the US who currently live with UC, as an effective medication could provide long-term relief from the symptoms associated with the disease. In addition, Triastek’s MED platform has the potential to revolutionize the pharmaceutical industry as a whole, as its ability to precisely and accurately produce medications could lead to more effective treatments and better outcomes for all. Triastek is now moving forward with the next stages of the trial process for T21. The company is hopeful that their efforts will lead to the approval and availability of the medication, and ultimately usher in a new era of safe and effective medicines for those living with UC. Triastek has set new heights in drug designing with the help of advanced-manufacturing. The designs, created using 3D printer technology, are specifically tailored to control where and when the medicine is absorbed in the body while giving them the opportunity to time-release powerful active ingredients. The latest development, T21, is directed towards the treatment of Ulcerative Colitis (UC). Unlike the existing treatments in the market, T21's design enables it to target the colon specifically. This could provide a major breakthrough towards treating UC and other similar conditions. Triastek has pioneered drug design through additive manufacturing and their success is evident from their developments. The system can be tailored for any medication and has shown tremendous potential to revolutionize the way drugs are delivered into our bodies. We are certain, T21 will soon bring hope among countless individuals suffering from UC and others related conditions. Triastek recently shared highly anticipated results from its FIH study that showed its investigational compound, T21, has shown to be successfully delivered and released directly to the colon. This finding is a breakthrough for ulcerative colitis (UC) patients and could have a major impact on patient treatments. The results of the study demonstrated that T21 tablets were successfully delivered and released in the colon. This is a significant advantage when compared to oral treatments that are not able to be directed to the affected area. The directed delivery to the colon also has the potential to provide significant safety, efficacy, and tolerability benefits to UC patients. In addition to these promising prospects for UC patients, these imaging results are the first step in Triastek’s efforts to pursue Food and Drug Administration (FDA) approval for T21. As part of the New Drug Application (NDA) process, Triastek must demonstrate that T21 can be delivered successfully and these imaging results are an important component of demonstrating that. Overall, Triastek’s findings have the potential to revolutionize UC treatments and accelerate its path towards FDA approval. These results provide hope to those living with UC and offer a significant development towards a safer, more effective treatment. Triastek, a leader in 3D printing based drug delivery technology development, has announced the successful completion of their FIH study of T21 for colon targeted drug delivery. In a statement about the completion of the study, Professor Xiaoling Li, co-founder and Chief Scientific Officer of Triastek, declared: “The study data with T21 verifies the precise colon delivery capability of the MED process, and the platform is set to become the novel drug delivery system of choice for colon targeted new products with either local efficacy or systemic absorption.” The aim of the study was to illustrate the performance, efficacy and safety of Triastek’s patented 3D printing based drug delivery system. The results of the FIH study showed that the MED platform was able to deliver drug quickly and accurately, allowing for greater efficiency and efficacy in the delivery of drug to patients. In addition, the study also established that the MED platform was able to provide sustained release of drug, making it more effective than traditional delivery methods. With the completion of their FIH study, Triastek is now poised to provide pharmaceutical companies with a more efficient platform for producing and delivering medications for optimized and patient-targeted drug delivery. Professor Li concluded: “We hope to continue showcasing how Triastek’s 3D printing processes can bring technical solutions to pharmaceutical companies for efficient product developmentg of optimized drug delivery, ultimately leading to the ability to provide patients with more clinically valuable medicines.” A conversation with Triastek's CEO, Dr. Senping Cheng, made me realize the potential of additive manufacturing, or AM, for pharmaceuticals. Through careful precision of the release site, T21 has the capability to reduce systemic exposure and minimize the risk of side effects from administering medicines throughout the body. This can lead to a safer and higher-quality product for users. Not only do these advantages take the healthcare industry a step forward, but they can translate to the cost savings for pharmaceutical companies and improved convenience for patients. AM is proving itself a crucial tool in many different industries, and the healthcare industry stands to benefit tremendously from the abilities of this technology. Three Reasons to Prioritize The Use of Automation in The Pharmaceuticals Industry## 1. Fast-Tracked Development: Automated solutions can be developed and deployed in a shorter timeframe than traditional processes, allowing for faster results. 2. Improved Accuracy: Automated machines are much more accurate than their manual counterparts, and they can be very precisely regulated to ensure consistent results. 3. Increased Supply: Automating production and manufacturing processes should help increase the supply of medications, allowing for an easier and more secure access for those in need. Despite the challenges associated with automated processes in the pharmaceuticals industry, the advantages could be great and make a difference when it comes to the supply of effective and safe medications—especially in the wake of global health crises. It is in everyone’s interest to try and find the right balance between fast-paced innovation and safety, so that we can secure a healthier and more prosperous future for everyone. Eli Lilly’s announcement earlier this year that it planned to collaborate with Triastek to research potential new applications for the MED platform serves as an important reminder of the challenges the company continues to face with regards to drug development and manufacturing. In April 2023, the FDA rejected its NDA for the new UC drug, mirikuzmab, citing issues related to quality control in Eli Lilly’s Branchburg, NJ manufacturing operations. Undeterred, Eli Lilly’s collaboration with Triastek is likely an attempt to move past this situation by creating a powerful new platform for drugs that can more efficiently get through the FDA approval process. This could ultimately provide much needed breakthroughs in the development of new treatments for conditions such as UC as well as many other chronic illnesses. Eli Lilly’s collaboration with Triastek is leading-edge and, if successful, could provide us with new pharmaceutical solutions to various diseases. With this in mind, we can only hope that Eli Lilly’s operations and processes are adjusted to the point that future FDA submissions are successful. ###Ethereal Natural Wonders - Photos from Triastek### The Triastek photo collection features some of the most breathtaking natural scenes you will ever witness. From towering trees gently swaying in the fog to meandering mountain pathways leading to a stunning panoramic view, these stunning images capture the beauty of the natural world. Whether you’re looking for some outdoor inspiration for your next adventure or simply need a reminder to relax and take in the beauty of nature, these photos serve as a wonderful reminder to take the time to appreciate the world around us. Are you looking to stay informed on the 3D printing industry and its latest innovations? Want to be the first to receive exclusive offers from industry vendors? Look no further! With this handy guide, you’ll be able to stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors. Subscribe to 3D printing newsletters – you’ll get a notification whenever new content is posted to the 3D printing websites and blogs. Sign up for industry vendors’ mailing lists – they’ll send you product updates and exclusive deals periodically. Follow 3D printing accounts on social media – you’ll receive news and information regarding industry developments, as well as discounts and offers. Join 3D printing forums – you’ll be able to network with industry professionals and get their valuable advice and opinions regarding the latest products and services. By signing up for these sources of news and information, you’ll not only stay up-to-date on the 3D printing industry, but you’ll also be the first to learn about exclusive offers and discounts from industry vendors. Happy printing!

Original source